

(1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally – **Not publicly available**

(2) the estimated volume of patients who may be prescribed the drug – **not publicly available**

(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval – **Breakthrough Therapy = no, Priority Review = no**

(4) the date and price of acquisition if the drug was not developed by the manufacturer – **N/A**